Gland Pharma Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2020
January 22, 2021 at 06:18 am
Share
Gland Pharma Limited announced unaudited earnings results for the third quarter and nine months ended December 31, 2020. For the quarter, the company reported revenue from operation of INR 8,594.19 million against INR 6,459.35 million a year ago. Profit for the period was INR 2,041.07 million or INR 12.82 per diluted share against INR 1,540.99 million or INR 9.95 per diluted share a year ago. Total income was INR 8,945.49 million against INR 6,712.23 million a year ago.
For the nine months, the company reported revenue from operation of INR 25,751.28 million against INR 19,980.02 million a year ago. Profit for the period was INR 7,365.54 million or INR 47.10 per diluted share against INR 5,780.65 million or INR 37.31 per diluted share a year ago. Total income was INR 26,626.90 million against INR 20,909.69 million a year ago.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
GLAND PHARMA LIMITED 
